Market access update
Navigating the US payer landscape and the evolving influence of ICER
Securing optimal reimbursement and patient access in the US is complex – and it’s likely to become even more complex over the months and years to come.
Here’s the good news: market access success doesn’t have to stretch your budgets or create more work. A great place to reinvigorate your thinking is this collection of landmark studies on the US payer landscape and the evolution of ICER’s influence.
This free collection of research and recommendations will help you:
- appreciate how changing US payer decision-making priorities may affect the pricing and reimbursement of your products
- understand the evolving impact of ICER evaluations for your market access strategies
- learn how technology is helping leading manufactures to unlock product value from early development through to successful commercialization.
Don’t jeopardize your US market access and commercial potential – read the research today or get in touch with us for a confidential conversation about your current challenges and PRMA Consulting’s solutions.
“We have made significant progress in integrated evidence generation planning and are benefiting from insight into new methods of evidence generation thanks to our work with PRMA Consulting.”
Associate Director, Market Access, top-5 pharmaceutical company
“Your discussion framework is a great way to move things forward. It helps uncover different stakeholder perspectives and encourages constructive conversation around all the important issues.”
Global Market Access Manager, top-5 pharmaceutical company
“I love it, I want it, I need it. You are the right company at the right time.”
Global Market Access Director, top-5 pharmaceutical company